Stocks and Investing
by (remove) : Matthew O'Brien
RSSJSONXMLCSV
Stocks and Investing
by (remove) : Matthew O'Brien
RSSJSONXMLCSV
Mon, July 1, 2024
Wed, May 8, 2024
Thu, January 5, 2023
Tue, August 2, 2022
Tue, May 3, 2022
Wed, March 2, 2022
Mon, February 7, 2022
Fri, January 8, 2021
Thu, November 5, 2020
Mon, September 21, 2020
Tue, August 4, 2020
Mon, May 11, 2020
Tue, January 7, 2020
Mon, August 5, 2019
Fri, July 27, 2018
Thu, May 24, 2018
Thu, November 2, 2017

Matthew O"Brien Downgraded (ZBH) to Hold and Decreased Target to $115 on, Jul 1st, 2024


Published on 2024-10-28 12:11:40 - WOPRAI, Matthew O'Brien
  Print publication without navigation


Matthew O"Brien of Piper Sandler, Downgraded "Zimmer Biomet Holdings, Inc." (ZBH) to Hold and Decreased Target from $140 to $115 on, Jul 1st, 2024.

Matthew has made no other calls on ZBH in the last 4 months.

There are 8 other peers that have a rating on ZBH. Out of the 8 peers that are also analyzing ZBH, 5 agree with Matthew"s Rating of Hold. Following are those relevant analyst calls for the last 4 months;

Mike Matson of "Needham" Reiterated at Hold on, Thursday, May 30th, 2024
David Roman of "Goldman Sachs" Initiated at Hold and Held Target at $129 on, Thursday, May 30th, 2024
Richard Newitter of "Truist Securities" Maintained at Hold with Decreased Target to $130 on, Friday, May 3rd, 2024
Vijay Kumar of "Evercore ISI Group" Maintained at Hold with Increased Target to $130 on, Thursday, April 4th, 2024
Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $140 on, Wednesday, April 3rd, 2024

These are the ratings of the 3 analyists that currently disagree with Matthew;

Matt Miksic of "Barclays" Maintained at Sell with Decreased Target to $125 on, Friday, May 31st, 2024
David Toung of "Argus Research" Upgraded from Hold to Strong Buy and Held Target at $150 on, Tuesday, May 21st, 2024
Steven Lichtman of "Oppenheimer" Maintained at Buy with Increased Target to $155 on, Friday, May 3rd, 2024

Contributing Sources